vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-547Research ArticleПРОБЛЕМЫ. МНЕНИЕ ЭКСПЕРТОВPROBLEMS. EXPERT OPINIONЗАЧЕМ НУЖНА ПЛАНОВАЯ ВАКЦИНАЦИЯ ДЕВОЧЕК-ПОДРОСТКОВ ПРОТИВ ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА?IS SYSTEMATIC VACCINATION OF GIRLS-ADOLESCENTS AGAINST HUMAN PAPILLOMA VIRUS NECESSARY?МинкинаГ. Н.MinkinaG. N.

Контактная информация: Минкина Галина Николаевна, доктор медицинских наук, профессор кафедры акушерства и гинекологии лечебного факультета Московского государственного медико-стоматологического университета Адрес: 127473, Москва, ул. Делегатская, д. 20/1, тел.: (499) 178-59-71, e-mail: minkinagn@mail.ru

minkinagn@mail.ruМосковский государственный медико-стоматологический университетРоссияMoscow State University of Medicine and DentistryRussian Federation201117012011101Вопросы современной педиатрии106110Copyright © Минкина Г.Н., 20112011Минкина Г.Н.Minkina G.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/547

Всемирная организация здравоохранения и Европейский центр по профилактике и контролю над заболеваемостью рекомендуют включение в национальные программы иммунизации рутинной вакцинации девочек против вируса папилломы человека. В статье рассматривается целесообразность плановой вакцинации как в странах с развитыми программами скрининга рака шейки матки, так и в обществах, где адекватный скрининг недоступен. Обсуждается возраст вакцинации, представлен зарубежный опыт внедрения ВПЧ-вакцины в национальные программы иммунизации.

World Health Organization and European Center of Prophylaxis and Control over Morbidity recommend inclusion of systematic vaccination against human papilloma virus in girls-adolescents in national immunization programs. The article makes a review of vaccination reasonability as in countries with developed programs of neck of uterus cancer, as in societies with absence of adequate screening. Author discusses the age of vaccination and presents a foreign experience of vaccine against human papilloma virus inclusion into National Immunization Programs.

рак шейки маткивакцинывирус простого герпесаиммунизацияneck of uterus cancervaccinesherpes simplex virusimmunizationГлаксоСмитКляйнReferencesParkin D. M., Bray F. The burden of HPV-related cancers // Vaccine. — 2006; 24 (3): 11–25.Parkin D. M., Bray F. The burden of HPV-related cancers // Vaccine. — 2006; 24 (3): 11–25.Peto J., Gilham C., Fletcher O., Matthews F. E. The cervical cancer epidemic that screening has prevented in the UK // Lancet. — 2004; 364 (9430): 249–56.Peto J., Gilham C., Fletcher O., Matthews F. E. The cervical cancer epidemic that screening has prevented in the UK // Lancet. — 2004; 364 (9430): 249–56.Monsonego J. Prevention of cervical cancer: screening, progress and perspectives // Press Med. — 2007; 36: 92–111.Monsonego J. Prevention of cervical cancer: screening, progress and perspectives // Press Med. — 2007; 36: 92–111.Gakidou E., Nordhagen S., Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities // PLoS Medicine. — 2008; 5 (6): 863–868.Gakidou E., Nordhagen S., Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities // PLoS Medicine. — 2008; 5 (6): 863–868.Cohen J. Public health. High hopes and dilemmas for a cervical cancer vaccine // Science. — 2005; 308 (5722): 618–21.Cohen J. Public health. High hopes and dilemmas for a cervical cancer vaccine // Science. — 2005; 308 (5722): 618–21.Chesson H. W., Blandford J. M., Gift T. L. et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000 // Perspect. Sex. Reprod. Health. — 2004; 36 (1): 11–19.Chesson H. W., Blandford J. M., Gift T. L. et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000 // Perspect. Sex. Reprod. Health. — 2004; 36 (1): 11–19.Arbyn M., Kyrgiou M., Simoens C. et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis // BMJ. — 2008; 337: 1284.Arbyn M., Kyrgiou M., Simoens C. et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis // BMJ. — 2008; 337: 1284.Злокачественные новообразования в России в 2009 году (заболеваемость и смертность) / под ред. В. И. Чиссова, В. В. Старинского, Г. В. Петровой. — М., 2011. — 260 с. URL: http://www.oncology.ru/service/statistics/Злокачественные новообразования в России в 2009 году (заболеваемость и смертность) / под ред. В. И. Чиссова, В. В. Старинского, Г. В. Петровой. — М., 2011. — 260 с. URL: http://www.oncology.ru/service/statistics/Harper D. M., Franco E. L., Wheeler C. M. et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial // Lancet. — 2006; 367: 1247–1255.Harper D. M., Franco E. L., Wheeler C. M. et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial // Lancet. — 2006; 367: 1247–1255.Ault K. A. Effect of prophylactic human papillomavirus L1 viruslikeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials // Lancet. — 2007; 369: 1861–1868.Ault K. A. Effect of prophylactic human papillomavirus L1 viruslikeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials // Lancet. — 2007; 369: 1861–1868.Villa L. L., Ault K. A., Giuliano A. R. et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18 // Vaccine. — 2006; 24 (27–28): 5571–5583.Villa L. L., Ault K. A., Giuliano A. R. et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18 // Vaccine. — 2006; 24 (27–28): 5571–5583.Pedersen C., Petaja T., Strauss G. et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant // J. Adolesc. Health. — 2007; 40 (6): 564–567.Pedersen C., Petaja T., Strauss G. et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant // J. Adolesc. Health. — 2007; 40 (6): 564–567.Einstein M. H., Baron M., Levin M. J. et al. Comparison of the immunogenicity and safety of cervarix and gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years // Hum. Vaccin. — 2009; 5 (10): 705–19.Einstein M. H., Baron M., Levin M. J. et al. Comparison of the immunogenicity and safety of cervarix and gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years // Hum. Vaccin. — 2009; 5 (10): 705–19.Schiller J. T., Lowy D. R. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials // J. Infect. Dis. — 2009; 200 (2): 166–71.Schiller J. T., Lowy D. R. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials // J. Infect. Dis. — 2009; 200 (2): 166–71.Olsson S. E., Villa L. L., Costa R. L. et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine // Vaccine. — 2007; 25: 4931–4939.Olsson S. E., Villa L. L., Costa R. L. et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine // Vaccine. — 2007; 25: 4931–4939.David M. P., van Herck K., Hardt K. et al. Long-term persistence of anti-HPV-16 and –18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses // Gynecol. Oncol. — 2009; 115 (3 Suppl): 1–6.David M. P., van Herck K., Hardt K. et al. Long-term persistence of anti-HPV-16 and –18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses // Gynecol. Oncol. — 2009; 115 (3 Suppl): 1–6.Paavonen J., Naud P., Salmeron J. et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women // Lancet. — 2009; 374 (9686): 301–14.Paavonen J., Naud P., Salmeron J. et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women // Lancet. — 2009; 374 (9686): 301–14.Wheeler C. M., Kjaer S. K., Sigurdsson K. et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years // J. Infect. Dis. — 2009; 199 (7): 936–944.Wheeler C. M., Kjaer S. K., Sigurdsson K. et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years // J. Infect. Dis. — 2009; 199 (7): 936–944.Reisinger K. S., Block S. L., Lazcano-Ponce E. et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial // Pediatr. Infect. Dis. J. — 2007; 26: 201–209.Reisinger K. S., Block S. L., Lazcano-Ponce E. et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial // Pediatr. Infect. Dis. J. — 2007; 26: 201–209.Garnett G. P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease // J. Infect. Dis. — 2005; 191 (1): 97–106.Garnett G. P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease // J. Infect. Dis. — 2005; 191 (1): 97–106.Stanley М. Human papillomavirus vaccines versus cervical cancer screening // Clin. Oncol. — 2008; 20 (6): 388–394.Stanley М. Human papillomavirus vaccines versus cervical cancer screening // Clin. Oncol. — 2008; 20 (6): 388–394.Annual HPV vaccine uptake in England: 2008/09. URL: http://www.dh.gov.uk/publicationsAnnual HPV vaccine uptake in England: 2008/09. URL: http://www.dh.gov.uk/publicationsBosch F. X., Castellsague X., de Sanjose S. HPV and cervical cancer: screening or vaccination? // Br. J. Cancer. — 2008; 98: 15–21.Bosch F. X., Castellsague X., de Sanjose S. HPV and cervical cancer: screening or vaccination? // Br. J. Cancer. — 2008; 98: 15–21.Kane M. A., Sherris J., Coursaget P. et al. HPV vaccine use in the developing world // Vaccine. — 2006; 24 (3): 132–139.Kane M. A., Sherris J., Coursaget P. et al. HPV vaccine use in the developing world // Vaccine. — 2006; 24 (3): 132–139.

The authors declare that there are no conflicts of interest present.